NCT03807414 is a clinical trial of oXiris in Critical Illness, sponsored by Careggi Hospital.

Who is sponsoring NCT03807414?

NCT03807414 is sponsored by Careggi Hospital.

What drugs are being tested in NCT03807414?

Interventions in NCT03807414: oXiris.

What condition does NCT03807414 study?

NCT03807414 studies Critical Illness, Acute Kidney Injury, Sepsis, Systemic Inflammatory Response Syndrome.

Is NCT03807414 still recruiting?

NCT03807414 is currently active, enrolled. Last updated 12 February 2025.

Last reviewed 2025-02-12 · How we verify

NCT03807414

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development of a Web-based Multicenter Registry on the Use of oXiris Membrane for EBPTs in Critically Ill Patients

Active, enrolled Last updated 12 February 2025

What this trial tests

trial testing oXiris in Critical Illness in 270 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

28 June 2019

Primary endpoint
30 September 2025

30 September 2025

Quick facts

Lead sponsor	Careggi Hospital
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	270
Start date	28 June 2019
Primary completion	30 September 2025
Estimated completion	30 September 2025
Sites	12 locations across Italy

Drugs / interventions tested

oXiris

Conditions studied

Critical Illness — all drugs for Critical Illness →
Acute Kidney Injury — all drugs for Acute Kidney Injury →
Sepsis — all drugs for Sepsis →
Systemic Inflammatory Response Syndrome — all drugs for Systemic Inflammatory Response Syndrome →

Sponsor

Careggi Hospital

Who can join

18 and older, any sex, with Critical Illness or Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The use of extracorporeal blood purification therapies (EBPT) is becoming increasingly widespread worldwide in everyday clinical practice, particularly in the critical care setting. Nonetheless, most of the clinical trials aimed at exploring the effect of EBPT on patients' long-term outcomes have failed to demonstrate consistent results regarding 28 day- or hospital- mortality rates. The aim of this observational prospective registry is to evaluate if there is a cluster of critically ill patients that mostly benefits from extracorporeal blood purification therapies with oXiris membrane.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Effect of Continuous Renal Replacement Therapy with the oXiris Hemofilter on Critically Ill Patients: A Narrative Review.
Li Y, Sun P, Chang K, Yang M, et al · · 2022 · cited 26× · PMID 36431196 · DOI 10.3390/jcm11226719
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.
Ramasco F, Nieves-Alonso J, García-Villabona E, Vallejo C, et al · · 2024 · cited 9× · PMID 38392609 · DOI 10.3390/jpm14020176
Use of Oxiris membrane in real-world clinical practice in critical care patients: a multicenter observational study.
Villa G, Fioccola A, Cecchi M, Scirè Calabrisotto C, et al · · 2025 · PMID 41398301 · DOI 10.1186/s44158-025-00305-3
Program of quality improvement for extracorporeal blood purification therapies in the intensive care unit.
Cecchi M, Pomarè Montin D, Fioccola A, Bocciero V, et al · · 2026 · PMID 41385006 · DOI 10.1007/s10877-025-01396-7
Dynamic CRRT Prescription for Complicated Critically Ill Patient: A Case Report.
Santorsola C, Corona A, Cecchi M, Nicolini NC, et al · · 2024 · PMID 39611098 · DOI 10.1155/2024/1837150
Navigating the Modern Landscape of Sepsis: Advances in Diagnosis and Treatment
Jang J, Choi E, Kim T, Yeo H, et al · · 2024

Verify or expand the search:

Other recruiting trials for Critical Illness

Currently open trials in the same condition.

NCT06189924 — Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients · recruiting
NCT07418242 — Prognostic Value of Novel Biomarkers on Adverse Renal Outcomes in High-Risk Cardiac Surgery Patients · recruiting
NCT07101640 — PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysp · Phase 1, PHASE2 · recruiting
NCT07177183 — Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure · NA · recruiting
NCT07369258 — Clinical Application of Listening to Music to Prevent Delirium in the Intensive Care Unit · NA · recruiting

Other Careggi Hospital trials

Trials by the same sponsor.

NCT04580680 — Extracorporeal Blood Purification Therapy in Critically Ill Patients (GlobalARRT) · recruiting
NCT04033224 — Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure · recruiting
NCT04341974 — Perioperative Use of Serum Creatinine and Postoperative Acute Kidney Injury · completed
NCT03820232 — Intraoperative Body Core Temperature Monitoring: Oesophageal Probe vs Heated Controlled Servo Sensor · completed
NCT03796338 — Sleep Quantity and Quality in the ICU: a Prospective Observational Stud · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03807414 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Careggi Hospital
Last refreshed: 12 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03807414.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing